Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

• Type of Material: Article
• Authors: Nicole Gormley, United States Food and Drug Administration; Lola Fashoyin-Aje, United States Food and Drug Administration; Trevan Locke, American Association for Cancer Research; Jospeh M Unger, Fred Hutchinson Cancer Research Center; Richard F Little, National Cancer Institute (NCI); Ajay Nooka, Emory University; Khalid Mezzi, Amgen Incorporated; Mihaela Popa-McKiver, Bristol-Myers Squibb; Rachel Kobos, Janssen, Raritan; Yelak Biru, Patient Research Advocate; Tiffany H Williams, DNP, APRN, CPNP-PC, Retired.; Kenneth C Anderson, Dana-Farber Cancer Institute
• Language: English
• Date: 2021-03-01
• Publisher: American Association for Cancer Research.
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: ©2021 American Association for Cancer Research.
• Final Published Version (URL): http://dx.doi.org/10.1158/2643-3230.BCD-20-0123
• Title of Journal or Parent Work: Cancer discovery
• Volume: 2
• Issue: 2
• Start Page: 119
• End Page: 124
• Keywords: clinical trial r; Multiple myeloma
• Research Categories: Health Sciences, Oncology

Abstract

African Americans are at higher risk of multiple myeloma (MM) yet are underrepresented in clinical trials and reap fewer benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, healthcare providers, patients, industry partners, and regulators at an FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a road map to addressing disparities broadly in clinical trials.